Puma Biotechnology earnings were $37.0M for the trailing 12 months ending Sep 30, 2025, with 56.3% growth year over year. The latest PBYI earnings report on Sep 30, 2025 announced Q3 2025 earnings of $8.8M, up 51.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PBYI reported annual earnings of $30.3M, with 40.2% growth.
PBYI past earnings growth
How has PBYI's earnings growth performed historically?
What were Puma Biotechnology's earnings last quarter?
On PBYI's earnings call on Invalid Date, Puma Biotechnology (NASDAQ: PBYI) reported Q3 2025 earnings per share (EPS) of $0.18, up 56.1% year over year. Total PBYI earnings for the quarter were $8.84 million. In the same quarter last year, Puma Biotechnology's earnings per share (EPS) was $0.41.
As of the last Puma Biotechnology earnings report, Puma Biotechnology is currently profitable. Puma Biotechnology's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $36.98 million, a 59.11% increase year over year.
What was PBYI's earnings growth in the past year?
As of Puma Biotechnology's earnings date in Invalid Date, Puma Biotechnology's earnings has grown 56.25% year over year. This is 3.34 percentage points lower than the US Biotechnology industry earnings growth rate of 59.59%. PBYI earnings in the past year totalled $36.98 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.